Business Context and Reporting Period
Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing the Proteograph Product Suite for proteomics, filed this Form 8-K on March 29, 2021. The filing reports financial results for the quarter and full year ended December 31, 2020. The company is an emerging growth company that recently completed its initial public offering (IPO) in December 2020 and a follow-on offering in February 2021.
Key Financial Metrics
| Metric | Q4 2020 | Q4 2019 | Full Year 2020 | Full Year 2019 |
|---|---|---|---|---|
| Revenue | $336,000 | $58,000 | $656,000 | $116,000 |
| Operating Expenses | $13.4 million | $5.5 million | $34.3 million | $17.0 million |
| Net Loss | $12.9 million | $5.1 million | $32.8 million | $16.0 million |
| Cash, Equivalents, and Investments | $431.9 million (as of Dec 31, 2020) | N/A | N/A | N/A |
| Net Proceeds from Financing | $314.4 million (IPO) | N/A | N/A | N/A |
Liquidity and Debt: As of December 31, 2020, total current liabilities were $8.1 million. The company holds no long-term debt listed on the balance sheet. Subsequent to year-end, the company raised an additional $103.1 million in net proceeds from a follow-on offering in February 2021.
Material Changes vs. Prior Period
- Revenue Growth: Q4 2020 revenue increased 479% year-over-year, driven by the completion of a research collaboration study. Full-year 2020 revenue increased 466%, attributed to an NIH Small Business Innovation Research grant and collaboration studies.
- Expense Expansion: Operating expenses rose 145% in Q4 2020 and 102% for the full year 2020. Increases were driven by higher headcount, stock-based compensation, product development for the Proteograph suite, and costs associated with becoming a public company.
- Net Loss: Net loss widened significantly, increasing 153% in Q4 2020 and 105% for the full year 2020 compared to prior periods.
- Balance Sheet: Total assets grew from $93.2 million in 2019 to $442.3 million in 2020, primarily due to cash inflows from the IPO and private placements.
Outlook, Commentary, and Risks
Management Commentary: Management highlighted the transition to "Limited Release" (Phase 2 of the commercialization plan) and the addition of new collaborators, including the Salk Institute and Discovery Life Sciences. The company also signed a commercial agreement with SCIEX and expanded its executive team and Board of Directors.
Guidance: The filing does not provide specific numerical financial guidance for future periods. Management expressed confidence in the market enthusiasm for the Proteograph Product Suite and the potential for deep, unbiased proteomic studies.
Risks and Contingencies: The press release includes standard forward-looking statement disclaimers. Risks include the timing and ability to enable unbiased, deep, and rapid proteomics at scale. The company notes that actual results may differ materially from expectations due to known and unknown risks detailed in its Form 10-K.
Investor Verification Checklist
- Verify the sustainability of revenue growth, which is currently driven by grants and specific research collaborations rather than broad commercial sales.
- Confirm the burn rate and runway given the significant increase in operating expenses (102% YoY) and the company's pre-revenue commercial status.
- Review the terms of the new commercial agreement with SCIEX and the status of pilot studies at OHSU Knight Cancer Institute and the Broad Institute.
- Assess the impact of stock-based compensation on future operating expenses as the company scales its workforce.
- Monitor the timeline for the transition from "Limited Release" to broader commercial availability of the Proteograph Product Suite.